<DOC>
	<DOCNO>NCT00257491</DOCNO>
	<brief_summary>To evaluate trough peak effect daily MICARDIS PLUS ( Telmisartan 80 mg/hydrochlorothiazide 12.5 mg ) 24 ABPM patient mild moderate essential hypertension .</brief_summary>
	<brief_title>Study Evaluate Trough Peak Effect Once Daily Telmisartan 80 mg/Hydrochlorothiazide 12.5 mg ( Micardis Plus ) Ambulatory Blood Pressure Monitoring ( ABPM ) Patients With Mild Moderate Essential Hypertension</brief_title>
	<detailed_description>This study design open label study . After 2-week placebo run-in phase , qualify patient administer telmisartan 80mg 2 week , forcefully titrate telmisartan 80 mg hydrochlorothiazide 12.5 mg fix dose combination 6 week . 24 hour ABPM perform end placebo run-in period ( baseline ) 8 week active treatment . Study Hypothesis : The primary analysis calculation trough peak ratio ( T/P ratio ) DBP SBP . The T/P ratio calculate basis change hourly mean ( relate dosing time ) baseline ( DeltaHM ) . Trough define mean last three hour 24-hour dose interval . Peak great reduction hourly mean hour 2 8 dosing . Thus , T/P calculate T/P = mean ( DeltaHM22 - DeltaHM24 ) /min ( DeltaHM2 - DeltaHM8 ) . Comparison ( ) : To assess trough/peak ratio daily Micardis plus 24 ABPM patient mild moderate essential hypertension .</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Telmisartan</mesh_term>
	<mesh_term>Hydrochlorothiazide</mesh_term>
	<criteria>1 . History mildtomoderate essential hypertension define mean seated DBP &gt; = 95 &lt; = 109 mmHg , SBP &lt; 180mmHg measure manual cuff sphygmomanometer visit 2 . Note : The manual cuff value calculate mean three seat measurement collect 2 minute apart , patient seat quietly 5 minute . For calculation mean value investigator , decimal place round integer usual ( e.g. , DBP 94.7 would round 95 mmHg DBP 109.3 would round 109 mmHg ) . 2 . Participants 18 80 year age . 3 . Ability provide write informed consent . 4.24 hour mean DBP &gt; = 85 mmHg visit 3 . 5.Ability stop current antihypertensive therapy without risk patient ( investigator discretion ) . 1 . Patients take three antihypertensive medication screen visit . 2 . Premenopausal woman ( last menstruation &lt; = 1 year prior start screen ) : Who surgically sterile ( hysterectomy , tubal ligation ) . Who NOT practice acceptable mean birth control NOT plan continue use acceptable method throughout study . Acceptable method birth control include IUD , oral , implantable injectable contraceptive . 3 . Any woman : Who positive urine pregnancy test screening ( Visit 1 ) . Who nurse . 4 . Hepatic and/or renal dysfunction define follow laboratory parameter : SGPT ( ALT ) SGOT ( AST ) great two time upper limit normal . Serum creatinine &gt; 3.0 mg/dL ( 265 mmol/L ) creatinine clearance &lt; 0.6 ml/sec . 5 . Clinically relevant hypokalaemia hyperkalaemia . 6 . Uncorrected volume depletion . 7 . Uncorrected sodium depletion . 8 . Hereditary fructose intolerance . 9 . Biliary obstructive disorder , cholestasis moderate severe hepatic insufficiency . 10 . Known suspected secondary hypertension . 11 . Bilateral renal artery stenosis ; renal artery stenosis solitary kidney ; postrenal transplant patient , presence one functioning kidney . 12 . Congestive heart failure ( NYHA functional class CHF IIIIV refer Appendix 11 . 1 ) . 13 . Unstable angina within past three month . 14 . Stroke within past six month . 15 . Myocardial infarction cardiac surgery within past three month . 16 . PTCA within past three month . 17 . Patients previously experience symptom characteristic angiodema treatment ACE inhibitor angiotensin II receptor antagonist . 18 . Sustained ventricular tachycardia , atrial fibrillation , atrial flutter clinically relevant cardiac arrhythmia determine investigator . 19 . Hypertrophic obstructive cardiomyopathy , aortic stenosis , hemodynamically relevant stenosis aortic mitral valve .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>November 2013</verification_date>
</DOC>